Back to catalogue
№ 347 32 filings · 2021-10-13 → 2026-10-05

QUARTIX TECHNOLOGIES PLC

QTX
Technology Share price 230p Market cap £111m Overall fit 420 /1000

Quality SaaS with fortress balance sheet, visible operating leverage and a fair-to-cheap valuation — but essentially no direct AI-receiver angle, which caps the fit against the investor's primary pillar. A good 'quality at a reasonable price' holding, not a thesis fit.

Fair value range 240p–290p Mid case · £129m
Absolute upside +15.3% vs current market cap
Conviction 4/5 confidence in undervalued call
Supports the call
  • Clean disclosed SaaS KPIs (ARR, NRR, cohort attrition) across every filing
  • Three valuation methods (ARR multiple, PE, EV/EBIT) all converge on ~£120-140m
  • Consistent track record of meeting/modestly beating guidance over 2024-2026
Limits the call
  • IAS 16 restatement makes multi-year EBITDA comparisons noisy
  • Fair value sensitive to Continental Europe growth sustaining 20%+ vs Germany/US drag
Methodology

Blend of 3-3.5x forward ARR, 15-17x PE and 14-16x EV/EBIT on 2026E

In one line · bull case

High-quality, net-cash, 97% recurring vehicle-telematics SaaS at 2.6x ARR / 17x PE with 4.4% dividend yield and genuine operating leverage, trading near 52-week lows after an accounting-driven de-rate.

In one line · biggest risk

Growth settles at 7-9% ARR as US/UK stagnate and Continental Europe fails to scale, leaving the current valuation roughly fair rather than cheap.

Drivers
AI beneficiary 25 /100
Vertical SaaS with no AI monetisation; only internal AI research spend of ~£0.1m — Quartix is an AI buyer, not seller.
Operating leverage 68 /100
80% gross margin, 97% recurring; fixed R&D and overhead base, but S&M scales with new customer acquisition — 10-20% revenue beat likely adds 30-60% to EBIT.
Earnings vs expectations 62 /100
Consistent in-line / modest beats across 2024-2026 trading updates and results.
Growth momentum 55 /100
Steady 11-14% ARR growth with Continental Europe accelerating but UK/US sluggish.
Moat 48 /100
Narrow — reputation, service quality (4.8 Trustpilot), modest switching costs; no network effects, limited pricing power (NRR <100%).
Earnings quality 60 /100
Clean cash conversion (EBITDA to CFO 100%+); offset by FRC-driven IAS 16 restatement and HMRC prior-year true-up.
Management quality 52 /100
Founder-led, service-focused; Konetik 2023 acquisition was fully impaired within 15 months; thin NED coverage.
Cyclicality 28 /100
SME fleet exposure gives some cyclicality but 97% recurring subscription revenue dampens it materially.
Leverage 10 /100
Net cash £5.3m, no debt, strong FCF generation — classic fortress.
Value-trap signals · 6
  • NRR persistently below 100% (96.9% H1 2026)
  • US subscription base contracting on TTM basis for ~3 years
  • FRC-driven IAS 16 accounting restatement in 2025 with HMRC prior-year adjustment
  • Auditor change (PKF to BDO) in Oct 2026
  • Konetik acquisition fully impaired within 15 months — mixed capital allocation record
  • Thin board governance (Executive Chairman + 2 NEDs)

QUARTIX TECHNOLOGIES PLC (QTX) — Investment Research Note

Executive summary

Quartix is a UK-listed, subscription-based vehicle telematics vendor serving ~34,000 SME fleet customers across 334,000 vehicles in six European markets and the US, generating ~97% recurring revenue. Across the period, ARR has compounded from ~£22m (end-2020) to ~£40m (Q3 2026) at a steady ~10–14% p.a. while EBIT margins have expanded materially (adj EBIT 2025: £8.8m vs 2020: ~£6m), aided by lower hardware unit costs, overhead discipline and the end of the loss-making Konetik distraction. The valuation debate today hinges on whether a 2.6x ARR / ~17x PE for a clean, net-cash, 80% gross-margin SaaS business is fair given moderate growth and no credible AI monetisation angle — on balance the shares look fair-to-modestly undervalued.

Fair value estimate

  • Range: 240p – 290p per share, implying mkt cap £116m – £141m.
  • Mid: ~265p / ~£128m.
  • Current: 228.85p / £109m. Mid upside ~+16%; range: +5% to +27%.

Methodology — triangulation of three approaches on 2026E numbers (revenue £40.3m, Adj EBIT £10.1m, FCF £4.9m, net cash ~£5m):

  1. ARR multiple: 3.0–3.5x 2026E ARR of £40m → £120–140m EV → 247–289p/share. Supported by Quartix being capital-light, 80% gross-margin, recurring-revenue 2026-07 interim; 2026-10-05 trading.
  2. P/E on 2026E EPS: 2025 EPS 13.18p 2026-03 final; 2026E ~13–14p after higher tax base. 15–17x → 195–238p.
  3. EV/EBIT: 14–16x on 2026E Adj EBIT £10.1m 2026-10-05 trading + net cash → 300–340p.

Weighted toward (1) and (2) given moderate growth; (3) represents the bull-case re-rating if operating leverage materialises.

Sector context

  • ICB Technology / Technology-Services confirmed; functionally this is vertical SaaS (fleet telematics).
  • Quality (balance sheet, GM, FCF conversion) is above typical AIM small-cap tech peers; growth (11% ARR) is in line with mid-tier SaaS peers but well below hyperscaler telematics (Samsara). Leverage is below peer average (net cash).
  • Listed peers: Microlise (SONDR.L), Powerfleet (AIOT), Samsara (IOT), Trakm8 (TRAK). Quartix is the smallest / most profitable of the Europe-listed set and trades at ~2.6x ARR vs Samsara ~12x and Microlise ~2–3x EV/Sales.

Investment thesis

  1. High-quality, net-cash SaaS available at a fair price. 97% recurring revenue, 80% H1 2026 gross margin, 25% operating margin, £5m+ net cash, 10p dividend (4.4% yield), and ARR +11% TTM to £39.7m 2026-10-05 trading. For a sticky B2B subscription business, 2.6x ARR / ~17x PE / 4.4% yield is undemanding.
  2. Operating leverage is now visible. 2025 adj EBIT grew 38% on revenue +12% 2026-03 final after Konetik was cleaned up and manufacturing cost of the TCSV17/18 fell by ~£8/unit. Management explicitly says incremental ARR flow-through is improving: cost savings "deferred" rather than reinvested in 2026 2026-10-05; Continental Europe territories (Italy +31%, Spain +22%, Germany +16%) are growing well above group average, which should pull group ARR growth higher through 2027.
  3. Fortress downside protection with multiple shots on goal. No debt, strong FCF, 2–3 year committed roadmap: 4G upgrade in France concluding 2026, dashcam launch in Continental Europe H1 2027, new UI commercial release early 2027 2026-07 interim. Even flat growth leaves the valuation defensible via dividends.

Key risks

  1. Mediocre growth could persist. NRR is still <100% (96.9% H1 2026 vs 98.1% FY 2025) 2026-07 interim and US revenue is flat/down (-3% TTM subscription base) 2026-10-05; UK TTM growth only 2%. If European territories don't scale, this becomes a 7–9% ARR grower where today's multiple is already roughly fair.
  2. Accounting / governance signals. FRC prompted a full IAS 16 restatement in 2025 reclassifying tracking units as PPE with a £1.1m prior-year HMRC adjustment 2026-07 interim; auditor changed from PKF to BDO Oct 2026 2026-10-05. Both are explicable but together suggest tighter scrutiny of a historically shareholder-friendly but small-board set-up (Executive Chairman + 2 NEDs only).
  3. No AI monetisation story. Only direct AI mention is a £0.1m internal spend on an AI "customer-acquisition efficiency" research project 2026-07 interim — i.e. Quartix is an AI buyer, not seller. If investors reallocate from "quality SaaS" toward "AI beneficiary SaaS", this name may underperform peers in a cycle up-leg.

Operating leverage

Quartix exhibits genuine but moderate operating leverage. H1 2026 cost base: cost of sales £3.9m (largely IAS 16 depreciation of hardware over 7 years + commissions), S&M £5.8m, admin £4.8m — roughly £10.6m fixed/semi-fixed overheads vs £19.4m revenue 2026-07 interim. Incremental ARR carries ~80% gross margin and limited incremental support cost given ARR/employee is already £220k and improving. A 10–20% revenue beat (£4–8m) above the £40.3m 2026 base would plausibly add £3–6m of adj EBIT, i.e. +30–60% on current £10m EBIT, consistent with the user's "long-tail upside" lens but not the "double your EBIT on 15% beat" extreme. The ceiling is capped by (a) manufacturing/installation unit costs that scale with volume, and (b) the need to keep adding field sales to drive growth. Dashcam upsell is the clearest contribution-margin inflection: the H1 2025 UK programme generated ~£0.5m of ARR purely from existing-base penetration 2025-10 trading at essentially 100% incremental GM.

Value-trap signals

  • NRR persistently <100% — base erodes without new wins to offset.
  • US subscription base shrinking for ~3 years despite management attention.
  • FRC-driven accounting restatement with tax true-up.
  • Konetik acquisition (2023) was fully impaired for £2.5m within 15 months — capital allocation track record is mixed.
  • Executive Chairman is also effectively CEO (founder returned in 2023), with just 2 NEDs — governance is thin for a public company.

None are terminal; cumulatively they explain why the stock trades at 2.6x ARR not 4x.

Earnings vs expectations

Looking across trading updates and prior consensus references:

  • FY 2024 2025-01 trading / 2025-03 final: delivered broadly in line with guidance; adj EBITDA £6.5m slightly ahead of previous £5.4m consensus; FCF £2.6m vs £3.4m expectation — mixed/in-line.
  • H1 2025 2025-07 interim: beat — EBITDA £3.7m vs £7.2m FY expectation implying H1 run-rate ahead; management upgraded profit and cash outlook.
  • FY 2025 2026-01 trading / 2026-03 final: beat — ARR +£4.5m vs implied £3.5m, revenue £35.7m vs ~£36.0m consensus (in line), adj EBITDA £13.2m well ahead of £7.7m pre-restatement consensus (noting the IAS 16 restatement inflates reported EBITDA).
  • H1 2026 2026-07 interim: in line / slight beat — confident in full-year £40.3m revenue / £10.1m adj EBIT consensus.
  • Q3 2026 2026-10-05 trading: modest beat — adj PBT "modestly ahead" of consensus.

Pattern: consistent record of meeting and modestly beating consensus over the last 24 months, with Konetik-era 2023 as the exception. Positive but not spectacular — this is a reliable "beat and raise by a touch" story.

Conviction

4 / 5 — High.

Anchors: (a) exceptionally clean disclosure (ARR, NRR, attrition, per-region unit metrics) across every filing; (b) multiple valuation methodologies converge on ~£120–140m; (c) consistent delivery track record vs guidance.

Limits: (a) IAS 16 restatement makes historical EBITDA comparisons across years tricky; (b) fair-value estimate is sensitive to whether Continental Europe growth accelerates (upside) or Germany/US drag persists (downside).

Filings consulted · 40

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-10-05Trading Statement2026-10-05_9805269_trading-statement.md0.85
  2. 2026-07-27Interim Results2026-07-27_9687593_interim-results.md0.90
  3. 2026-07-08Trading Statement2026-07-08_9657144_trading-statement.md0.85
  4. 2026-04-22Trading Statement2026-04-22_9531417_trading-statement.md0.85
  5. 2026-04-22Result OF Agm2026-04-22_9533523_result-of-agm.md0.30
  6. 2026-03-25Final Results2026-03-25_9490311_final-results.md0.85
  7. 2026-01-08Trading Update2026-01-08_9340091_trading-update.md0.72
  8. 2025-10-06Trading Statement2025-10-06_9151398_trading-statement.md0.55
  9. 2025-07-24Interim Results2025-07-24_8996403_interim-results.md0.58
  10. 2025-07-03Trading Statement2025-07-03_8961168_trading-statement.md0.55
  11. 2025-04-07Trading Statement2025-04-07_8816041_trading-statement.md0.55
  12. 2025-03-31Result OF Agm2025-03-31_8805928_result-of-agm.md0.20
  13. 2025-03-31Agm Trading Statement2025-03-31_8804101_agm-trading-statement.md0.55
  14. 2025-03-03Final Results2025-03-03_8758857_final-results.md0.65
  15. 2025-02-13Investor Presentation Via Investor Meet Company2025-02-13_8735594_investor-presentation-via-investor-meet-company.md0.46
  16. 2025-01-13Trading Statement2025-01-13_8684163_trading-statement.md0.55
  17. 2024-10-15Trading Statement2024-10-15_8485777_trading-statement.md0.55
  18. 2024-07-29Interim Results2024-07-29_8334600_interim-results.md0.41
  19. 2024-07-08Trading Statement2024-07-08_8297949_trading-statement.md0.38
  20. 2024-03-27Result OF Agm2024-03-27_8110630_result-of-agm.md0.14
  21. 2024-03-27Agm Trading Statement And Directorate Change2024-03-27_8108582_agm-trading-statement-and-directorate-change.md0.38
  22. 2024-03-04Final Results2024-03-04_8067446_final-results.md0.45
  23. 2024-01-09Trading Statement2024-01-09_7980157_trading-statement.md0.38
  24. 2023-10-06Trading Update2023-10-06_7800192_trading-update.md0.21
  25. 2023-09-15Acquisition OF Konetik Gmbh2023-09-15_7757064_acquisition-of-konetik-gmbh.md0.19
  26. 2023-07-31Interim Results2023-07-31_7664098_interim-results.md0.23
  27. 2023-07-10Interim Results Timetable And Trading Update2023-07-10_7621645_interim-results-timetable-and-trading-update.md0.23
  28. 2023-03-24Result OF Agm2023-03-24_7331327_result-of-agm.md0.07
  29. 2023-03-24Agm Trading Statement2023-03-24_7280396_agm-trading-statement.md0.21
  30. 2023-02-27Final Results2023-02-27_7235717_final-results.md0.25
  31. 2023-01-11Trading Statement2023-01-11_7392214_trading-statement.md0.21
  32. 2022-10-10Trading Update2022-10-10_7255657_trading-update.md0.21
  33. 2022-07-27Interim Results2022-07-27_7179671_interim-results.md0.23
  34. 2022-07-11Interim Results Timetable And Trading Update2022-07-11_6923349_interim-results-timetable-and-trading-update.md0.23
  35. 2022-03-23Result OF Agm2022-03-23_7049566_result-of-agm.md0.07
  36. 2022-03-23Agm Trading Statement2022-03-23_7006189_agm-trading-statement.md0.21
  37. 2022-02-28Final Results2022-02-28_6959902_final-results.md0.25
  38. 2022-01-10Trading Statement2022-01-10_6805707_trading-statement.md0.21
  39. 2021-10-22Ceo Succession Update And Trading Update2021-10-22_6525843_ceo-succession-update-and-trading-update.md0.21
  40. 2021-10-13Ceo Succession Update And Trading Update2021-10-13_6766401_ceo-succession-update-and-trading-update.md0.21

This research note was authored by a large language model after reading 32 regulatory filings published between 2021-10-13 and 2026-10-05. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.